Your session is about to expire
← Back to Search
Radioactive Agent
I-MIBG Therapy for Neuroblastoma
Phase 2
Waitlist Available
Research Sponsored by National Center for Research Resources (NCRR)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Inclusion criteria: Refractory neuroblastoma with original diagnosis based on tumor histopathology or elevated urine VMA with typical tumor cells in the bone marrow
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing a new medication, 131I-metaiodobenzylguanidine (131I-MIBG), to see if it can help children with neuroblastoma who have relapsed or who are unresponsive to other treatments.
Who is the study for?
This trial is for children with neuroblastoma, a type of cancer that forms in certain types of nerve tissue. Participants must have specific tumor cells in their bone marrow and elevated urine VMA, an indicator of the disease. The study is focused on those whose neuroblastoma has not responded to previous treatments.Check my eligibility
What is being tested?
The trial tests a high dose (18 mCi/kg) of I-Metaiodobenzylguanidine (I-MIBG), which is like norepinephrine and targets adrenergic tissue where neuroblastoma occurs. It's given to see if it can effectively treat children with relapsed or stubborn neuroblastoma at two medical institutions.See study design
What are the potential side effects?
Possible side effects include reduced thyroid function due to radiation uptake, low blood cell counts leading to increased infection risk or bleeding problems, nausea, vomiting, and fatigue from the treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
National Center for Research Resources (NCRR)Lead Sponsor
537 Previous Clinical Trials
317,016 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My neuroblastoma is not responding to treatment and was confirmed by tests.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Will elderly individuals be recruited for this research project?
"This study is open to very young patients, with the age limit being set at 0 years old."
Answered by AI
Has this procedure been okayed by the FDA?
"While there is some evidence that this intervention is safe, it is only supported by data from a Phase 2 trial, which means that there is no current evidence that it is effective."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger